ASCEND Study of Natalizumab Efficacy on Disability in Patients with Secondary Progressive Multiple Sclerosis (SPMS): Baseline Demographics and Disease Characteristics

被引：0
|
作者：
Mikol, Daniel
Freedman, Mark S.
Goldman, Myla D.
Hartung, Hans-Peter
Havrdova, Eva
Jeffery, Douglas
Kapoor, Raj
Miller, Aaron
Sellebjerg, Finn
Lee, Sophia
Chen, Yun
Cadavid, Diego
Ticho, Barry
机构：
来源：
ANNALS OF NEUROLOGY | 2013年 / 74卷
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
引用
下载
收藏
页码：S59 / S60
页数：2
相关论文
共 50 条
  • [1] ASCEND study of natalizumab efficacy on reducing disability in patients with secondary progressive multiple sclerosis: baseline demographics and disease characteristics
    Mikol, D.
    Freedman, M. S.
    Goldman, M. D.
    Hartung, H-P
    Havrdova, E.
    Jeffery, D.
    Kapoor, R.
    Miller, A.
    Sellebjerg, F.
    Lee, S.
    Chen, Y.
    Cadavid, D.
    Ticho, B.
    MULTIPLE SCLEROSIS JOURNAL, 2013, 19 (11) : 507 - 508
  • [2] Effect of natalizumab on disability progression in patients with non-active secondary progressive multiple sclerosis in ASCEND
    Chen, Z.
    Gafson, A.
    Belachew, S.
    Riester, K.
    MULTIPLE SCLEROSIS JOURNAL, 2021, 27 (2_SUPPL) : 214 - 215
  • [3] ASCEND Phase 3 Trial Open-Label Extension Study Results: Natalizumab May Delay Disability Progression in Secondary Progressive Multiple Sclerosis (SPMS)
    Hartung, Hans-Peter
    Arnold, Douglas
    Freedman, Mark
    Havrdova, Eva
    Jeffery, Douglas
    Kapoor, Raju
    Miller, Aaron
    Sellebjerg, Finn
    Li, Haihong
    Lucas, Nisha
    Cadavid, Diego
    Campbell, Nolan
    Ho, Pei-Ran
    Steiner, Deborah
    NEUROLOGY, 2017, 88
  • [4] Sustained disability improvement in patients with secondary progressive multiple sclerosis (SPMS) assessed by a multicomponent endpoint: a post hoc analysis from the ASCEND study
    Giovannoni, G.
    Steiner, D.
    Sellebjerg, F.
    Cohan, S.
    Jeffery, D.
    Rog, D.
    Chen, Y.
    Dong, Q.
    Ho, P. -R.
    Cadavid, D.
    Amarante, D.
    MULTIPLE SCLEROSIS JOURNAL, 2016, 22 : 671 - 672
  • [5] Effects of Alemtuzumab on Disability and Cognition in Patients with Secondary Progressive Multiple Sclerosis (SPMS)
    Berkovich, Regina
    NEUROLOGY, 2017, 88
  • [6] Sustained Disability Improvement as Assessed by a Multicomponent Endpoint in Secondary Progressive Multiple Sclerosis (SPMS) Patients: A Post Hoc Analysis from ASCEND
    Giovannoni, Gavin
    Steiner, Deborah
    Sellebjerg, Finn
    Cohan, Stanley
    Jeffery, Douglas
    Rog, David
    Chen, Yi
    Dong, Qunming
    Ho, Pei-Ran
    Campbell, Nolan
    Cadavid, Diego
    Amarante, Diogo
    NEUROLOGY, 2017, 88
  • [7] The MS-COG, a novel endpoint for measurement of cognitive function in multiple sclerosis clinical trials: baseline characteristics of the cognitive substudy of the ASCEND natalizumab secondary progressive multiple sclerosis study
    Cadavid, D.
    Brochet, B.
    Mancardi, G. L.
    Nocentini, U.
    Kaushik, T.
    Xu, L.
    Chen, Y.
    Mikol, D.
    Ticho, B.
    MULTIPLE SCLEROSIS JOURNAL, 2013, 19 (11) : 508 - 508
  • [8] Siponimod (BAF312) for the treatment of secondary progressive multiple sclerosis (SPMS): baseline characteristics of the EXPAND study population
    Kappos, L.
    Bar-Or, A.
    Cree, B.
    Fox, R.
    Giovannoni, G.
    Gold, R.
    Vermersch, P.
    Bhasin, P.
    Arnould, S.
    Sidorenko, T.
    Wallstroem, E.
    MULTIPLE SCLEROSIS JOURNAL, 2015, 21 : 317 - 318
  • [9] Natalizumab Reduces Serum Concentrations of Neurofilament Light Chain in Secondary Progressive Multiple Sclerosis Patients From the Phase 3 ASCEND Study
    Kapoor, Raju
    Sellebjerg, Finn
    Hartung, Hans-Peter
    Arnold, Douglas
    Freedman, Mark S.
    Jeffery, Douglas
    Miller, Aaron
    Edwards, Keith R.
    Singh, Carol M.
    Chang, Ih
    Ren, Zhang
    Sangurdekar, Dipen
    Zhu, Bing
    Mehta, Devangi
    Ho, Pei-Ran
    Campbell, Nolan
    Edwards, Michael
    Fisher, Elizabeth
    Kieseier, Bernd C.
    Rudick, Richard A.
    Plavina, Tatiana
    NEUROLOGY, 2019, 92 (15)
  • [10] Natalizumab reduced serum levels of neurofilament light chain in secondary progressive multiple sclerosis patients from the phase 3 ASCEND study
    Kapoor, R.
    Sellebjerg, F.
    Hartung, H. -P.
    Arnold, D. L.
    Freedman, M. S.
    Jeffery, D.
    Miller, A.
    Edwards, K. R.
    Singh, C. M.
    Chang, I.
    Ren, Z.
    Sangurdekar, D.
    Zhu, B.
    Sheikh, S.
    Mehta, D.
    Ho, P. -R.
    Campbell, N.
    Edwards, M.
    Fisher, E.
    Kieseier, B. C.
    Rudick, R. A.
    Plavina, T.
    MULTIPLE SCLEROSIS JOURNAL, 2018, 24 : 988 - 988
12345